tiprankstipranks
Trending News
More News >
Mankind Pharma Ltd. (IN:MANKIND)
:MANKIND
India Market
Advertisement

Mankind Pharma Ltd. (MANKIND) AI Stock Analysis

Compare
10 Followers

Top Page

IN:MANKIND

Mankind Pharma Ltd.

(MANKIND)

Select Model
Select Model
Select Model
Neutral 66 (OpenAI - 4o)
Rating:66Neutral
Price Target:
₹2,720.00
▲(13.11% Upside)
Mankind Pharma's strong financial performance is the most significant factor driving the stock score, supported by solid revenue and profit growth. However, the technical analysis indicates mixed signals, and the high P/E ratio raises valuation concerns, which temper the overall score.

Mankind Pharma Ltd. (MANKIND) vs. iShares MSCI India ETF (INDA)

Mankind Pharma Ltd. Business Overview & Revenue Model

Company DescriptionMankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. Mankind Pharma Limited was founded in 1986 and is based in New Delhi, India.
How the Company Makes MoneyMankind Pharma generates revenue primarily through the sale of its pharmaceutical and healthcare products. The company has a robust revenue model that includes direct sales to healthcare providers, retail pharmacies, and hospitals, complemented by a strong export business. Key revenue streams include prescription medications, OTC products, and nutraceuticals. Additionally, Mankind engages in strategic partnerships and collaborations with other pharmaceutical companies and distributors, enhancing its market reach and product offerings. The company's focus on innovation and expanding its product portfolio, particularly in high-demand therapeutic areas, significantly contributes to its earnings.

Mankind Pharma Ltd. Financial Statement Overview

Summary
Mankind Pharma has demonstrated strong financial performance with robust revenue growth and impressive profit margins. The company maintains effective operational efficiency and sound cash flow management, supported by a stable balance sheet with low leverage.
Income Statement
85
Very Positive
Mankind Pharma has shown robust revenue growth with a significant increase of 18.14% in 2025 compared to 2024. The company's gross profit margin remains strong at 71.41%, and the net profit margin is healthy at 16.31%. EBIT and EBITDA margins are impressive at 49.37% and 24.73%, respectively, showcasing effective operational efficiency.
Balance Sheet
78
Positive
The debt-to-equity ratio is well managed at 0.59, indicating prudent leverage. Return on equity is commendable at 13.89%, reflecting efficient use of equity capital. The equity ratio is strong at 51.62%, ensuring financial stability and low risk. The company's balance sheet reflects a solid financial position with a strong equity base.
Cash Flow
80
Positive
The company exhibits a sound cash flow position with a free cash flow growth rate of 10.32%. The operating cash flow to net income ratio stands at 1.21, demonstrating good cash flow generation capability. The free cash flow to net income ratio is also robust at 0.98, indicating strong cash flow relative to net earnings.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue129.56B122.07B103.35B87.43B77.82B62.14B
Gross Profit84.65B87.18B70.14B33.88B53.12B43.89B
EBITDA34.10B30.18B28.09B20.27B21.47B18.17B
Net Income18.93B19.91B19.13B12.82B14.33B12.65B
Balance Sheet
Total Assets0.00277.60B119.63B97.15B91.48B63.73B
Cash, Cash Equivalents and Short-Term Investments25.25B22.45B34.56B15.29B12.79B20.04B
Total Debt0.0085.11B2.07B1.70B8.73B2.41B
Total Liabilities-145.68B131.91B23.87B20.67B28.31B15.10B
Stockholders Equity145.68B143.32B93.63B74.35B61.55B47.22B
Cash Flow
Free Cash Flow0.0019.53B17.70B9.53B-14.26B8.25B
Operating Cash Flow0.0024.13B21.52B17.85B9.20B11.37B
Investing Cash Flow0.00-126.92B-20.82B-10.54B-13.69B-12.22B
Financing Cash Flow0.00102.33B52.66M-7.40B6.05B-78.11M

Mankind Pharma Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2404.70
Price Trends
50DMA
2509.81
Negative
100DMA
2489.99
Negative
200DMA
2467.92
Negative
Market Momentum
MACD
-23.81
Negative
RSI
45.39
Neutral
STOCH
23.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANKIND, the sentiment is Negative. The current price of 2404.7 is below the 20-day moving average (MA) of 2447.47, below the 50-day MA of 2509.81, and below the 200-day MA of 2467.92, indicating a bearish trend. The MACD of -23.81 indicates Negative momentum. The RSI at 45.39 is Neutral, neither overbought nor oversold. The STOCH value of 23.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MANKIND.

Mankind Pharma Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
₹630.26B18.580.36%7.76%-2.84%
₹1.27T23.630.82%6.40%25.27%
₹993.45B21.731.10%14.52%9.46%
₹877.48B23.700.62%12.40%63.16%
₹1.21T60.490.89%7.63%15.39%
₹1.02T53.210.04%21.66%-4.92%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:MANKIND
Mankind Pharma Ltd.
2,444.60
-220.95
-8.29%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,112.70
-278.08
-19.99%
IN:CIPLA
Cipla Ltd
1,580.75
43.98
2.86%
IN:LUPIN
Lupin Limited
1,921.10
-251.65
-11.58%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
3,600.00
428.67
13.52%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
1,001.35
10.85
1.10%

Mankind Pharma Ltd. Corporate Events

Mankind Pharma Reports No Share Dematerialisation Requests for Q3 2025
Oct 5, 2025

Mankind Pharma Limited has announced that it has not received any requests for dematerialisation or rematerialisation of shares for the quarter ending September 30, 2025. This update, certified by KFin Technologies Limited, aligns with the company’s adherence to SEBI (Depositories and Participants) Regulations, 2018, ensuring transparency and compliance in its share management practices.

Mankind Pharma Ltd. Sees Withdrawal of CGST Penalty
Sep 10, 2025

Mankind Pharma Ltd. announced that the penalty of ₹2,90,70,363 imposed by the CGST Commissionerate, Meerut, for the financial years 2017-18 to 2021-22, has been withdrawn following an appeal. This development is likely to have a positive impact on the company’s financial standing and may enhance its reputation among stakeholders by demonstrating effective legal and regulatory compliance.

Mankind Pharma to Engage with Investors at Jefferies India Forum
Sep 9, 2025

Mankind Pharma Ltd. has announced its participation in the upcoming Jefferies 4th India Forum, scheduled for September 17, 2025, in Gurugram. The event will include one-on-one and group meetings, allowing the company’s management to engage with investors. This participation underscores Mankind Pharma’s proactive approach to investor relations and its commitment to transparency, although no unpublished price-sensitive information will be disclosed during the conference.

Mankind Pharma Receives ‘Adequate’ ESG Rating from Crisil
Aug 22, 2025

Mankind Pharma Ltd. has received an ESG rating of ‘Crisil ESG 57’ from Crisil ESG Ratings & Analytics Limited, indicating an ‘adequate’ level of environmental, social, and governance practices. This rating reflects the company’s efforts in maintaining transparency and responsibility in its operations, potentially impacting its reputation and attractiveness to investors focused on sustainable practices.

Mankind Pharma Releases Q1 FY26 Investor Call Transcript
Aug 6, 2025

Mankind Pharma Ltd. released the transcript of its Q1 FY26 investor conference call, highlighting the company’s financial performance and strategic direction. The call, led by key executives, provided insights into the company’s operations and market positioning, potentially impacting stakeholders’ perspectives on its future growth and industry influence.

Mankind Pharma Seeks Reclassification of Promoter Group
Aug 3, 2025

Mankind Pharma Ltd. has submitted an application to reclassify Ayushi and Poonam Estates LLP from the ‘Promoter & Promoter Group’ category to the ‘Public’ category. This move is part of the company’s strategic efforts to align with regulatory requirements and potentially enhance its market positioning by broadening its public shareholder base.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 25, 2025